$52.66
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Crinetics Pharmaceuticals
CRNXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock, Analyst Ratings, Price Targets, Forecasts
Crinetics Pharmaceuticals Inc has a consensus price target of $63.31 based on the ratings of 13 analysts. The high is $97 issued by Piper Sandler on July 2, 2024. The low is $39 issued by SVB Leerink on May 26, 2022. The 3 most-recent analyst ratings were released by JP Morgan, Piper Sandler, and HC Wainwright & Co. on July 9, 2024, July 2, 2024, and June 28, 2024, respectively. With an average price target of $70.33 between JP Morgan, Piper Sandler, and HC Wainwright & Co., there's an implied 33.56% upside for Crinetics Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Piper Sandler
HC Wainwright & Co.
JMP Securities
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Crinetics Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/09/2024 | Buy Now | 2.54% | JP Morgan | Jessica Fye | $47 → $54 | Maintains | Overweight | Get Alert |
| 07/02/2024 | Buy Now | 84.2% | Piper Sandler | Yasmeen Rahimi | $97 → $97 | Maintains | Overweight | Get Alert |
| 06/28/2024 | Buy Now | 13.94% | HC Wainwright & Co. | Douglas Tsao | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 51.92% | JMP Securities | Jonathan Wolleben | $80 → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/04/2024 | Buy Now | 40.52% | Oppenheimer | Leland Gershell | $55 → $74 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 13.94% | HC Wainwright & Co. | Douglas Tsao | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 13.94% | HC Wainwright & Co. | Douglas Tsao | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 17.74% | Baird | Brian Skorney | $52 → $62 | Maintains | Outperform | Get Alert |
| 05/23/2024 | Buy Now | 32.93% | Morgan Stanley | Jeffrey Hung | $50 → $70 | Maintains | Overweight | Get Alert |
| 05/14/2024 | Buy Now | 23.43% | Cantor Fitzgerald | Josh Schimmer | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 51.92% | JMP Securities | Jonathan Wolleben | → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/10/2024 | Buy Now | 13.94% | HC Wainwright & Co. | Douglas Tsao | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 84.2% | Piper Sandler | Yasmeen Rahimi | $56 → $97 | Maintains | Overweight | Get Alert |
| 03/28/2024 | Buy Now | 51.92% | JMP Securities | Jonathan Wolleben | → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2024 | Buy Now | 4.44% | Oppenheimer | Leland Gershell | $54 → $55 | Maintains | Outperform | Get Alert |
| 03/20/2024 | Buy Now | 51.92% | JMP Securities | Jonathan Wolleben | $60 → $80 | Maintains | Market Outperform | Get Alert |
| 03/20/2024 | Buy Now | 13.94% | HC Wainwright & Co. | Douglas Tsao | $50 → $60 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 6.34% | JonesTrading | Lina Kaminski | $52 → $56 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | -5.05% | HC Wainwright & Co. | Douglas Tsao | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | -5.05% | HC Wainwright & Co. | Douglas Tsao | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 2.54% | Oppenheimer | Leland Gershell | $48 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | -5.05% | HC Wainwright & Co. | Douglas Tsao | $42 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 29.13% | Citigroup | David Lebovitz | → $68 | Initiates | → Buy | Get Alert |
| 03/04/2024 | Buy Now | 23.43% | Cantor Fitzgerald | Josh Schimmer | $50 → $65 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 13.94% | JMP Securities | Jonathan Wolleben | $50 → $60 | Maintains | Market Outperform | Get Alert |
| 02/29/2024 | Buy Now | -8.85% | Oppenheimer | Leland Gershell | $46 → $48 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | -1.25% | Baird | Brian Skorney | $45 → $52 | Maintains | Outperform | Get Alert |
| 02/02/2024 | Buy Now | -5.05% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/16/2024 | Buy Now | -5.05% | Morgan Stanley | Jeffrey Hung | → $50 | Initiates | → Overweight | Get Alert |
| 12/19/2023 | Buy Now | -5.05% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | -20.24% | HC Wainwright & Co. | Douglas Tsao | → $42 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | -5.05% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | Buy Now | -33.54% | JP Morgan | Jessica Fye | → $35 | Reinstates | → Overweight | Get Alert |
| 10/24/2023 | Buy Now | -5.05% | Cantor Fitzgerald | Charles Duncan | $52 → $50 | Assumes | → Overweight | Get Alert |
| 09/14/2023 | Buy Now | -37.33% | HC Wainwright & Co. | Douglas Tsao | → $33 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | -12.65% | Oppenheimer | Leland Gershell | $40 → $46 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | -14.55% | Baird | Brian Skorney | $43 → $45 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | -8.85% | Evercore ISI Group | Maneka Mirchandaney | $41 → $48 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | -37.33% | HC Wainwright & Co. | Douglas Tsao | → $33 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | -24.04% | Oppenheimer | Leland Gershell | → $40 | Initiates | → Outperform | Get Alert |
| 08/22/2023 | Buy Now | -14.55% | Cantor Fitzgerald | Charles Duncan | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | -37.33% | HC Wainwright & Co. | Douglas Tsao | → $33 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | -20.24% | JMP Securities | Jonathan Wolleben | $43 → $42 | Maintains | Market Outperform | Get Alert |
| 08/09/2023 | Buy Now | -37.33% | HC Wainwright & Co. | Douglas Tsao | $35 → $33 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | -14.55% | Cantor Fitzgerald | Charles Duncan | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2023 | Buy Now | -33.54% | HC Wainwright & Co. | Douglas Tsao | → $35 | Reinstates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | -18.34% | JMP Securities | Jonathan Wolleben | → $43 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/08/2023 | Buy Now | -33.54% | HC Wainwright & Co. | Douglas Tsao | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | -18.34% | JMP Securities | Jonathan Wolleben | $41 → $43 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | -33.54% | HC Wainwright & Co. | Douglas Tsao | → $35 | Reiterates | → Buy | Get Alert |
| 04/24/2023 | Buy Now | 6.34% | Piper Sandler | Yasmeen Rahimi | → $56 | Initiates | → Overweight | Get Alert |
| 03/30/2023 | Buy Now | -8.85% | Baird | Brian Skorney | → $48 | Initiates | → Outperform | Get Alert |
| 03/01/2023 | Buy Now | -22.14% | JMP Securities | Jonathan Wolleben | $50 → $41 | Maintains | Market Outperform | Get Alert |
| 03/01/2023 | Buy Now | -33.54% | HC Wainwright & Co. | Douglas Tsao | → $35 | Reiterates | → Buy | Get Alert |
| 05/26/2022 | Buy Now | -25.94% | SVB Leerink | Joseph Schwartz | $36 → $39 | Maintains | Outperform | Get Alert |
| 03/31/2022 | Buy Now | -14.55% | JMP Securities | Jonathan Wolleben | $43 → $45 | Maintains | Market Outperform | Get Alert |
| 11/30/2021 | Buy Now | -18.34% | JMP Securities | Jonathan Wolleben | — | Initiates | → Market Outperform | Get Alert |
| 11/23/2021 | Buy Now | 29.13% | Evercore ISI Group | Maneka Mirchandaney | — | Initiates | → Outperform | Get Alert |
| 11/08/2021 | Buy Now | -33.54% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Crinetics Pharmaceuticals (CRNX) stock?
The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by JP Morgan on July 9, 2024. The analyst firm set a price target for $54.00 expecting CRNX to rise to within 12 months (a possible 2.54% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crinetics Pharmaceuticals (CRNX)?
The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by JP Morgan, and Crinetics Pharmaceuticals maintained their overweight rating.
When was the last upgrade for Crinetics Pharmaceuticals (CRNX)?
There is no last upgrade for Crinetics Pharmaceuticals
When was the last downgrade for Crinetics Pharmaceuticals (CRNX)?
There is no last downgrade for Crinetics Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Crinetics Pharmaceuticals (CRNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.
Is the Analyst Rating Crinetics Pharmaceuticals (CRNX) correct?
While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a maintained with a price target of $47.00 to $54.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $52.66, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.